BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT)

Equities researchers at BTIG Research initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. BTIG Research’s price objective points to a potential upside of 143.47% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $61.60.

Arcturus Therapeutics Price Performance

ARCT opened at $16.84 on Tuesday. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The company has a market capitalization of $456.20 million, a P/E ratio of -7.59 and a beta of 2.63. The firm’s fifty day moving average price is $17.26 and its two-hundred day moving average price is $19.54.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same period in the previous year, the business earned ($0.61) EPS. On average, equities research analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of ARCT. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 846 shares during the period. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics in the third quarter worth about $42,000. China Universal Asset Management Co. Ltd. raised its holdings in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 2,038 shares during the last quarter. Nordea Investment Management AB lifted its position in Arcturus Therapeutics by 3.7% during the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 2,335 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Arcturus Therapeutics by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after purchasing an additional 3,224 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.